Clinical trials: Crohn's Disease, Active
Crohn Disease
A Dose-finding Study of OPC-6535 in Patients With Active Crohn's Disease
The purpose of this study to examine the safety and efficacy of OPC-6535 and determine its optimal dose by once-daily oral administration at 0, 25, or 50 mg for 8 weeks in combination with a fixed oral dose of 5-aminosalicylic…
- Trial name
- NCT00317369
- Testing
- OPC-6535(Tetomilast)
- Where
- 8 sites in Japan
- Volunteers
- 29 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Inflammatory Bowel Disease, Ulcerative Colitis
Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease
The investigators hypothesize that E-health - web based monitoring of disease and treatment - in young patients with chronic inflammatory disease (IBD) can improve the disease course and quality of life.
- Conditions
- Inflammatory Bowel Disease, Ulcerative Colitis, Crohn´s Disease
- Trial name
- NCT01860651
- Testing
- Web-monitoring
- Where
- Denmark
- Volunteers
- 103 people
- Sponsor
- Hvidovre University Hospital
Crohn's Disease
An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective upadacitinib is in treating moderately to severely active CD in real world.
- Trial name
- NCT06023030
- Where
- 104 sites in Japan
- Volunteers
- 240 people
- Sponsor
- AbbVie
Crohn's Disease
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.
- Trial name
- VIVID-1 (NCT03926130)
- Testing
- Mirikizumab, Ustekinumab
- Where
- 580 sites in United States, Argentina and 32 more
- Volunteers
- 1,158 people
- Sponsor
- Eli Lilly and Company
Inflammatory Bowel Diseases, Crohn Disease
Exploration of the Activity of DNA Located Outside of Cellular Nucleus to Amplify Inflammation in Inflammatory Bowel Disease in Children Through Biological Pathway Cyclic GMP-AMP Synthase (cGAS) - Stimulator of Interferon Genes (STING)
Frequency of Inflammatory Bowel Diseases in children (IBD)-Crohn's disease (CD), Ulcerative colitis (UC) is constantly increasing.
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- ROXANE (NCT05916274)
- Testing
- Blood and fecal samples, Coolonic biopsies
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Inflammatory Bowel Diseases, Ulcerative Colitis
Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis
The primary aims of this phase I/II, randomized, placebo controlled study are the assessment of safety and tolerability of universal donor FMT compared to placebo in pediatric and young adult subjects (ages 5 years through 30…
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
- Trial name
- NCT02330653
- Testing
- Fecal Microbiota Transplant (FMT)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stacy A. Kahn
Crohn Disease
A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the pharmacokinetics (PK) of ustekinumab in subjects from 2 through less than (<) 18 years old in the USA, or 6 through less than (<) 18 years old in other countries and determine if it is…
- Trial name
- STELARA (NCT02968108)
- Testing
- Ustekinumab
- Where
- 26 sites in United States, Belgium and 4 more
- Volunteers
- 45 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease
This is a multi-centre, randomized, double-blind, dose response clinical study of CDP870 in patients with Crohn's disease.
- Trial name
- NCT00291668
- Testing
- Certolizumab Pegol
- Where
- 22 sites in Japan
- Volunteers
- 94 people
- Sponsor
- UCB Pharma
Crohn Disease
CD-TREAT Diet: a Novel Therapy for Active Luminal Crohn's Disease
Crohn's disease (CD) is a chronic inflammatory condition of the gut with severe complications. There is strong evidence to suggest that diet and gut bacteria are key components in the onset, perpetuation and management of CD.
- Trial name
- NCT03171246
- Testing
- Solid food-based intervention
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- NHS Greater Glasgow and Clyde
Intestinal Disorder, Inflammatory Bowel Diseases
Effect of Acupuncture on Mild to Moderate Active Crohn's Disease
To observe the clinical effect of acupuncture on Crohn's disease (CD) and its influence on brain function activity and the TRY-KYN metabolism level, and to screen the brain image markers of acupuncture on CD
- Conditions
- Intestinal Disorder, Inflammatory Bowel Diseases, Crohn Disease
- Trial name
- NCT04187820
- Testing
- acupuncture
- Where
- 2 sites in China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute of Acupuncture, Moxibustion and Meridian
Crohn Disease
Fecal Microbiota Transplantation in Pediatric Crohn's Disease
This study will test the safety and effectiveness of fecal microbiota transplantation (FMT) plus partial enteral nutrition (PEN) in refractory pediatric Crohn's disease (CD) who have failed conventional treatment
- Trial name
- FMT (NCT05321745)
- Testing
- Standardized FMT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Biao Zou
Crohn Disease
Exclusion Diet vs corticosteroIds in patientS With activE Crohn's Disease
Crohn's disease exclusion diet (CDED) is a whole-food diet coupled with partial enteral nutrition. The main objective of this trial is to assess whether CDED is superior to corticosteroids, in terms of endoscopic response, in…
- Trial name
- PARADISE (NCT05284136)
- Testing
- Crohn's disease exclusion diet (CDED), Oral prednisolone
- Where
- 2 sites in France, Netherlands
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Crohn's Disease (CD)
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab.
- Trial name
- NCT04779320
- Testing
- Vedolizumab IV
- Where
- 96 sites in United States, Australia and 16 more
- Volunteers
- 120 people
- Sponsor
- Takeda
Crohn's Disease
Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease
ISIS 2302 is an antisense oligonucleotide drug that reduces the production of a specific protein called intercellular adhesion molecule (ICAM-1), a substance that plays a significant role in the increase of inflammation.
- Trial name
- NCT00048113
- Testing
- Alicaforsen
- Where
- 30 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft…
- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias
- Trial name
- PRO-RIC (NCT04528355)
- Testing
- data collection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Paul Szabolcs
Crohn Disease
Personalising Anti-TNF Therapy in Crohns Disease (PANTS)
To develop a cost-effective, individualised anti-TNF treatment strategy for patients with Crohn's disease which maximizes benefit and minimises harm.
- Trial name
- PANTS (NCT03088449)
- Where
- United Kingdom
- Volunteers
- 1,750 people
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Crohn Disease (CD), Ulcerative Colitis (UC)
IBD Biomarker Discovery and Validation Platform
The goal of this observational study is to establish a multicenter prospective clinical and biospecimen platform for biomarker discovery and validation in inflammatory bowel disease, including Crohn's disease and ulcerative…
- Conditions
- Crohn Disease (CD), Ulcerative Colitis (UC), Inflammatory Bowel Diseases (IBD)
- Trial name
- IBD-BIOP (NCT07686406)
- Where
- 2 sites in China
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Crohn's Disease
Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy
This study investigated the expression of T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) in the colonic mucosa and/or the peripheral blood of children with Crohn's disease during anti TNF-α (infliximab)…
- Trial name
- NCT01661257
- Testing
- Infliximab
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Crohn's Disease
Bronchial Hyperreactivity in Children With Crohn Disease
Background: Latent pulmonary involvement is described in Crohn Disease(CD). Bronchial hyperreactivity measured by the Methacholine Challenge Test (MCT) has been evaluated in two studies involving mainly adults.Our aim was to…
- Trial name
- NCT01297907
- Testing
- Methacholine Challenge Test, Fractional Exhaled NO (FENO), Blood Test
- Where
- Israel
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Crohn's Disease
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active CD.
- Trial name
- NCT03104413
- Testing
- risankizumab SC, risankizumab IV
- Where
- 403 sites in United States, Argentina and 41 more
- Volunteers
- 618 people
- Sponsor
- AbbVie